Danaher Corporation (DHR) Stock Analysis 2026

Danaher is a science and technology company operating three platforms: Biotechnology (Cytiva — bioprocessing equipment for biologics manufacturing), Life Sciences (analytical instruments, lab consumables), and Diagnostics (point-of-care testing, water quality, environmental testing). The company is famous for the Danaher Business System (DBS) — a set of lean manufacturing and continuous improvement tools that Danaher applies to acquired companies to drive operating improvement. Danaher spun off its Environmental & Applied Solutions segment as Veralto in 2023.

This chart shows how Danaher's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Danaher Corporation trades at a trailing P/E of 38.45x, generates $4.33B in free cash flow, runs a debt/equity ratio of 52.97, and converts shareholder equity into profit at a 7.6% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

23 analysts covering Danaher Corporation currently lean toward a Strong Buy rating, with a mean 12-month price target of $227.96 (-3.8% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

We use 1 valuation model to estimate DHR's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

DHR is currently in a short-term uptrend, trading above its 50-day average of $199.70 and above its 200-day average of $203.06. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

DHR's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.

Research and guides that put DHR’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.

In-depth reports on companies operating alongside DHR — business models, bull and bear cases, and the metrics that matter.